This week ACOEP joined forces with the AOA to issue a statement in response to the FDA’s request for input regarding abuse potential, actual abuse, medical usefulness, trafficking and impact of scheduling changes on the availability for medical use of 10 drug substances – including ketamine. As the front line of emergency medicine, ACOEP is in an excellent position to offer excellent insight and to lend a voice in shaping national health policy on this important issue. The FDA will review all expert input and use this as a major factor as they draft a response to the World Health Organization.

Click here to read the joint statement.